ALK in cancer: from function to therapeutic targeting

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Anaplastic lymphoma kinase (ALK) is a key oncogenic driver in various cancers.
• ALK-expressing tumors initially respond to ALK inhibitors but often develop resistance.

Purpose of the Study:

• To review advances in ALK oncogenic signaling.
• To discuss current and novel therapeutic strategies for ALK-driven tumors.
• To explore combination approaches to overcome treatment resistance.

Main Methods:

• Review of current literature on ALK inhibitors and resistance mechanisms.
• Analysis of emerging therapeutic modalities, including immunotherapies.
• Discussion of combination strategies targeting ALK and co-existing pathways.

Main Results:

• ALK inhibitors have significantly impacted ALK+ tumor management but are not curative.
• Tumor resistance, recurrence, and metastasis remain significant challenges.
• Novel approaches like ALK-specific immunotherapies show promise.

Conclusions:

• A combination strategy targeting ALK and supporting pathways, alongside immunotherapy, is crucial for improving outcomes.
• Lessons from ALK+ tumors can inform treatments for other tyrosine kinase-driven cancers.
• Further research is needed to develop curative therapies and prevent resistance.